Literature DB >> 17108224

Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation.

Naoyuki Umetani1, Suzanne Hiramatsu, Dave S B Hoon.   

Abstract

Circulating DNA isolated from serum and plasma has been shown to be a useful biomarker in various diseases including cancer. Serum reportedly contains a higher amount of free circulating DNA than it does in plasma. The underlying reason for this is unclear, but important because it may have clinical implications in interpreting results and using the appropriate resource. Twenty-four pairs of serum and plasma samples were collected from patients with tumors, and free circulating DNA was quantified by real-time quantitative PCR (qPCR) for the ALU repeats, which had a sensitivity of 0.1 pg/microL of DNA in serum/plasma. The possibility of DNA loss was eliminated because ALU-qPCR does not require DNA purification from serum/plasma. The DNA concentrations of serum and plasma samples were 970 +/- 730 pg/microL and 180 +/- 150 pg/microL (mean +/- SD), respectively. The amount of DNA in paired serum and plasma specimens was positively correlated (R = 0.72 and P = 0.0002). An estimated 8.2% of total DNA in serum was extraneous; the concentration of DNA was 6.1 +/- 3.5 (mean +/- SD)-fold higher in serum than in paired plasma after subtraction of it. Contribution of extraneous DNA from cells in blood ruptured during the separation step was minor for explaining the difference between serum and plasma. A possible explanation was unequal distribution of DNA during separation from whole blood. We advocate that serum is a better specimen source for circulating cancer-related DNA as a biomarker.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108224     DOI: 10.1196/annals.1368.040

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  34 in total

1.  LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.

Authors:  Ana Aparicio; Brittany North; Lindsey Barske; Xuemei Wang; Valentina Bollati; Daniel Weisenberger; Christine Yoo; Nizar Tannir; Erin Horne; Susan Groshen; Peter Jones; Allen Yang; Jean-Pierre Issa
Journal:  Epigenetics       Date:  2009-04-06       Impact factor: 4.528

2.  Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma.

Authors:  Jian Chen; Mingjie Gong; Shendong Lu; Futian Liu; Liang Xia; Dekang Nie; Feihui Zou; Jinlong Shi; Shaoqing Ju; Longxiang Zhao; Hao Zuo; Jing Qi; Wei Shi
Journal:  J Mol Neurosci       Date:  2013-05-10       Impact factor: 3.444

3.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

4.  Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients.

Authors:  Jong-Lyul Park; Hyun Ja Kim; Bo Youl Choi; Han-Chul Lee; Hay-Ran Jang; Kyu Sang Song; Seung-Moo Noh; Seon-Young Kim; Dong Soo Han; Yong Sung Kim
Journal:  Oncol Lett       Date:  2012-02-03       Impact factor: 2.967

5.  Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.

Authors:  Swati Kumari; Shikha Tewari; Nuzhat Husain; Akash Agarwal; Anshuman Pandey; Ashish Singhal; Mohtashim Lohani
Journal:  Pathol Oncol Res       Date:  2016-07-30       Impact factor: 3.201

6.  Evaluation of an Improved Non-invasive Fetal Sex Determination in Haemophilia A Patients.

Authors:  Narmin Mokari-Zadeh; Seyed Alireza Mesbah-Namin
Journal:  J Clin Diagn Res       Date:  2015-07-01

7.  Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.

Authors:  Iris Lavon; Miri Refael; Bracha Zelikovitch; Edna Shalom; Tali Siegal
Journal:  Neuro Oncol       Date:  2010-02-01       Impact factor: 12.300

Review 8.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 9.  Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

Authors:  Giulia De Maio; Claudia Rengucci; Wainer Zoli; Daniele Calistri
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.